Skip to content
Head to head

Teva Pharmaceutical Industries vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: TEVA · TAK

Updated 8 minutes ago

1-year performance, rebased to 100

TEVA +59.5%TAK +56.6%
Teva Pharmaceutical Industries edges it on the scoreable measures. Teva Pharmaceutical Industries has the highest Quant Rating (91); Teva Pharmaceutical Industries has done best over the past year (+62%); Teva Pharmaceutical Industries trades cheapest on trailing earnings.
TEVATAK
Snapshot
Sector----
Last price39.2321.77
Change today+1.79%+1.68%
1-year return+61.6%+57.5%
Market cap$45.77B$69.76B
52-week range24.34 – 44.5713.92 – 22.07
Valuation
P/E (TTM)91.23311.00
P/E percentile, own 5-yr range99th100th
P/B5.741.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)1.21-0.30
Net profit (TTM)$1.41B$-970.94M
Revenue (TTM)$17.23B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-1.9%+6.7%
Gross margin53.5%65.8%
Operating margin19.2%14.3%
Net margin2.9%0.9%
Free cash flow (TTM)$1.23B$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership79.4%51.3%
Insider activity (12mo)23 buy / 24 sell19 buy / 31 sell
Short interest (% of float)2.4%0.1%
Analyst consensus100% buy (13)100% buy (1)
Analyst price target$52 (+31%)$50 (+132%)
StockVane view
StockVane Quant RatingC (91)C (90)
Company
Employees33,95047,029
Founded19011781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.